Biodesix (BDSX) Earnings Date & Reports

Key Takeaways

• Biodesix reported third-quarter 2025 revenue of $21.8 million, up 20% year over year and ahead of the roughly $21.0 million consensus estimate.
• Gross margin expanded to 81%, a 400-basis-point improvement from 77% in the prior-year period, driven by cost reductions per test.
• The net loss narrowed to $8.7 million, while adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) improved to a loss of $4.6 million, an 18% gain versus a year ago.
• Management raised full-year 2025 revenue guidance to $84 million–$86 million and said it expects adjusted EBITDA to turn positive in the fourth quarter.
• The company ended the quarter with $16.6 million in cash and cash equivalents, with development services revenue nearly doubling to $1.9 million.
• For more context on this ticker's Major News, Today's Price Move, Price Targets, and Forecast, explore the dedicated pages for deeper analysis and data.
• Discover related trade ideas and momentum signals by exploring Trending AI Robots.

Earnings Context and Why It Matters

Biodesix is a diagnostic solutions company focused on lung disease, generating revenue primarily from blood-based lung cancer tests and services for biopharmaceutical partners. Its latest quarterly earnings matter because they show whether the company can keep expanding test volumes while tightening losses on its path toward profitability. Recent quarters have featured accelerating revenue growth, margin gains, and a deliberate expansion of its sales force. Investors are watching closely whether that commercial momentum, combined with a recovery in Medicare Advantage claim payments and a fast-growing development services business, can translate into sustainable cash-flow improvement. The results also offer a signal on broader demand for precision lung diagnostics in an evolving reimbursement and regulatory environment.

Reported Results

For the third quarter ended September 30, 2025, Biodesix reported total revenue of $21.8 million, a 20% increase from $18.2 million a year earlier and above the consensus estimate of roughly $21.0 million. Lung diagnostic testing revenue rose 16% to $19.8 million, supported by approximately 15,700 tests (up 13% year over year) and a higher average revenue per test. Development services revenue surged 97% to $1.9 million, and the company exited the quarter with $12.9 million under contract but not yet recognized, an all-time high.

Gross margin improved to 81%, up 400 basis points from 77% in the prior-year quarter. The net loss narrowed to $8.7 million, a 15% improvement, and adjusted EBITDA improved 18% to a loss of $4.6 million. On a per-share basis, the company reported a loss of $1.16, better than the consensus estimate of a $1.60 loss. Management also raised full-year 2025 revenue guidance to $84 million–$86 million and guided to adjusted EBITDA positivity in the fourth quarter.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to help identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors tracking names like Biodesix, it offers a practical way to surface comparable opportunities and monitor shifting momentum across the diagnostic and healthcare sectors.

Market Reaction and Investor Sentiment

The market responded favorably to the report, with the stock advancing sharply in the session following the November 3, 2025 release. The revenue beat, expanded gross margin, raised guidance, and the outlook for fourth-quarter adjusted EBITDA positivity were key drivers of the positive reaction. Investor sentiment also appeared supported by management's commentary that a large Medicare Advantage plan resumed paying current claims and that primary care test ordering continues to grow. It is worth noting that the company completed a 1-for-20 reverse stock split in September 2025 to regain compliance with Nasdaq listing requirements, which remains part of the broader context for the share price. Despite the upbeat tone, lingering concerns around cash reserves and ongoing net losses temper the narrative.

Forward Outlook and Key Factors to Monitor

Looking ahead, the central question is whether Biodesix can convert its commercial momentum into adjusted EBITDA positivity in the fourth quarter and sustain that trajectory into 2026. The company has guided to 93–97 sales representatives in the field during the fourth quarter and expects gross margins to remain near 80%. Continued growth in lung diagnostic test volumes and average revenue per test will be critical to hitting the raised full-year revenue range of $84 million–$86 million.

Investors should also monitor the development services pipeline. The company's $12.9 million in contracted-but-unrecognized revenue represents a growing, higher-margin opportunity, though the timing of recognition can vary. Reimbursement dynamics remain important as well; management is still working to collect on older Medicare Advantage claims that were not previously booked as revenue, and any back-payments could provide a tailwind.

Finally, watch cash and liquidity. Biodesix ended the quarter with $16.6 million in unrestricted cash and has relied on debt and its at-the-market equity program to fund operations. The company's ability to narrow its losses while investing in sales expansion and clinical studies will shape both its balance sheet and investor confidence in the quarters ahead.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations